Page 8 - Read Online
P. 8
www.cdrjournal.com
Special Issue
Epigenetic Basis of Cancer Drug Resistance
Guest Editor: Special Issue Introduction
Aamir Ahmad, PhD Cancer is a deadly disease and resistance to therapies is a major reason that
Mitchell Cancer Institute, renders it particularly lethal. Some cancer patients are inherently resistant to
University of South Alabama, specific therapy because of their genetic makeup (de novo cancer drug
Mobile, Alabama, USA resistance) while other cancer patients initially respond to therapy, but
Website: eventually develop resistance with continued administration (acquired cancer
https://scholar.google.com/citat drug resistance). A good understanding of cancer drug resistance is critical to
ions?user=DjoXAZkAAAAJ&hl=en the efficient management of cancer patients in the clinics. A majority of
Email: research so far has focused on genetic factors that form the basis of cancer
aahmad@health.southalabama. drug resistance. However, it is increasingly being realized that epigenetic
edu regulation plays a very important in determining the resistance of individual
tumors to certain therapies. Methylation and acetylation are two well-studied
epigenetic events that are known to profoundly affect the expression of genes,
resulting in activation of oncogenes and/or suppression of tumor suppressor
genes, leading to development of cancer drug resistance. DNA methylation,
histone modifications (methylation, acetylation, phosphorylation, ubiquitylation,
sumoylation etc) as well as regulation through microRNAs (miRNAs) are some of
the active areas of cancer research, encompassing the epigenetic regulation.
A number of novel drugs, that target epigenetic events, are under investigation,
thus serving as a testimony to the enormous potential of exploiting epigenetics in
tackling the problem of cancer drug resistance.
This special issue welcomes novel research and detailed review articles
addressing the progress made in our understanding of epigenetic basis of
cancer drug resistance. This issue will also serve as a platform to discuss the
promises as well as unique challenges specific to this field of cancer research. All
the submitted articles will undergo rigorous peer review and will be published
free of charge upon acceptance.
Benefits
Rigorous mechanism in peer review: one manuscript must be reviewed by at
least two relevant experts. We will endeavour to ensure high standards for the
review process and subsequent publication by a team of efficient and
professional reviewers and scientific editors.
No publication fee: there would be absolutely no charge for publication.
Rapid publication: we will ensure that accepted papers will be published in a
short processing time (the average processing time: 50.7 days) with a high
quality.
Open Access: As an author you will retain the copyright to your work. By
licensing your work under the Creative Commons Attribution License, articles
can be re-used and re-distributed without restriction, as long as the original
work is correctly cited.
Wide promotions: Published articles will be promoted at academic
conferences, through social networks for scientists and relevant indexing
services.
245 E Main Street ste122, Alhambra, CA 91801, USAĠ www.cdrjournal.com
Telğ+1 323 9987086ĠE-mailğeditorial@cdrjournal.com
